Study identifier:9238IL/0065
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A Randomized, Open-label, Multicenter, Phase II Study Comparing the Effects on Proliferation and the Efficacy and Tolerability of Fulvestrant (FASLODEX®) 500 mg with Fulvestrant (FASLODEX®) 250 mg when given as Neoadjuvant Treatment in Postmenopausal Women with Estrogen Receptor Positive Breast Cancer (T2, 3, 4b, N0-3, M0).
Breast Cancer
Phase 2
No
Fulvestrant
Female
179
Interventional
N/A
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: 1 250 mg fulvestrant | Drug: Fulvestrant 250 mg & 500 mg intramuscular injection Other Name: FASLODEX™ Other Name: ZD9238 |
Experimental: 2 500 mg fulvestrant | Drug: Fulvestrant 250 mg & 500 mg intramuscular injection Other Name: FASLODEX™ Other Name: ZD9238 |